Get started
Author

Angela Joubert James

Observed names: Angela J James, Angela J. James, Angela James
ORCID: 0009-0003-4509-5787
Observed ORCID: 0009-0003-4509-5787
OpenAlex ID: A5067072967
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
2020 · Angela Joubert James, Catherine C. Smith, et al. · Clinical Pharmacokinetics · 73
PDF
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML
2023 · Keith W. Pratz, Mohamad Cherry, et al. · Journal of Clinical Oncology · 51
PDF
A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results
2020 · Keith W. Pratz, Mohamad Cherry, et al. · Blood · 30
Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid tumors.
2013 · Andrea Varga, Monica M. Mita, et al. · Journal of Clinical Oncology · 20
CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma
2014 · Vincent Ribrag, Silvia Damien, et al. · Blood · 12
Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase 1 expansion (exp) cohort.
2023 · Jason J. Luke, Manish Sharma, et al. · Journal of Clinical Oncology · 11
An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.
2017 · Alexander E. Perl, Jorge E. Cortes, et al. · Journal of Clinical Oncology · 10
A First In Human Dose Escalation Study Of CC-122, A First-In-Class Pleiotropic Pathway Modulator™ (PPM) Compound In Subjects With Relapsed Or Refractory Solid Tumors, Multiple Myeloma and Non-Hodgkin’s Lymphoma
2013 · Drew W Rasco, Anita K Gandhi, et al. · Blood · 9
A phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy.
2017 · Jorge E. Cortes, Jessica Altman, et al. · Journal of Clinical Oncology · 8
Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM).
2013 · Andre Goy, Vincent Ribrag, et al. · Journal of Clinical Oncology · 7
A phase 3, open-label, randomized study of the FLT3 inhibitor gilteritinib versus salvage chemotherapy in adults with first relapse or primary refractory FLT3 mutation-positive acute myeloid leukemia.
2016 · Alexander E. Perl, Jorge E. Cortes, et al. · Journal of Clinical Oncology · 6
Pharmacokinetics and pharmacodynamics of gilteritinib in patients with relapsed or refractory acute myeloid leukemia.
2016 · Catherine Choy Smith, Mark J. Levis, et al. · Journal of Clinical Oncology · 6
Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
2021 · Angela Joubert James, Catherine C. Smith, et al. · Clinical Pharmacokinetics · 1
PDF
A Novel Approach to QTc Studies: Assessing Cardiac Safety of the mTOR Kinase Inhibitor CC-223 within the Dose-Escalation/Expansion Study
2015 · Robert B Kleiman, Rajesh Chopra, et al. · Blood
Correlation of intratumoral metabolic changes measured with 18F-FDG PET parametric response maps with concentrations of CC-223, a TORC 1/2 kinase inhibitor, in human glioblastoma.
2014 · Benjamin M. Ellingson, Timothy Francis Cloughesy, et al. · Journal of Clinical Oncology
Works count: 15
Citation count: 244
H-index: 8
I10-index: 7
Year
Topic
Type